Using metformin to treat diabetes after chronic pancreatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of metformin in patients diagnosed with post chronic pancreatitis diabetes mellitus (PPDM-C). Participants will be randomly assigned to receive either metformin or a placebo to assess its impact on glycemic control and the incidence of adverse effects. The study aims to address the lack of standardized management strategies for PPDM-C, which is a condition that arises in a significant number of chronic pancreatitis patients. By focusing on this specific patient population, the trial seeks to provide insights into effective treatment options.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18-65 years, any sex.
2. Patients diagnosed with chronic pancreatitis.
3. Diagnose diabetes at least 3 months after chronic pancreatitis diagnosis.
4. Never used any diabetes drug/glucose-lowering medication or had discontinued any glucose-lowering medications for at least 8 weeks prior to screening.
5. HbA1c criteria: 7.5%\~9.0%.
6. BMI \>18.5.
7. Provision of signed informed consent.

Exclusion Criteria:

1. Type 1 diabetes or secondary diabetes not caused by chronic pancreatitis (e.g. diabetes due to monogenic defects, cystic fibrosis, medications, autoimmune diseases, stress, or other factors).
2. Contraindications or history of intolerance or allergy to metformin.
3. Fasting C-peptide \<0.3 nmol/L.
4. Acute episodes of chronic pancreatitis at enrollment or within 3 months prior to enrollment.
5. History of congestive heart failure (NYHA class 3 or greater), unstable angina, or other severe cardiovascular diseases.
6. History of cancer (except non-melanoma skin cancer) within 5 years prior to screening.
7. History of partial or total pancreatectomy.
8. History of or planning bariatric surgery.
9. Previous organ transplantation.
10. Treatment with oral or systemic glucocorticoids within 3 months prior to enrollment or plan to use during the study (inhaled steroids are permitted).
11. History of hemolytic anemia, chronic transfusion requirements, or other conditions rendering HbA1c results unreliable.
12. Other conditions requiring glucose-lowering medications, such as polycystic ovary syndrome.
13. Fasting blood glucose \>11.1 mmol/L during screening, requiring immediate treatment as judged by the physician.
14. Sever psychiatric disorders or health conditions deemed unsuitable for clinical research participation.
15. Pregnancy or plans for pregnancy during the course of the study.
16. Any other condition considered by the investigator to be inappropriate for participation in the trial.

Where it's running

• Changhai Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Lianghao Hu, M.D. — Changhai Hospital
• Study coordinator: Lianghao Hu, M.D.
• Email: lianghao-hu@smmu.edu.cn
• Phone: +86-13817593520

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CBT-248 safety in healthy adults for chronic pancreatitis support

  This early study tests CBT-248 in healthy adults to see if it is safe, how it behaves in the body, and whether meals affect its levels.

  Recruiting Phase 1 Cibus Therapeutics, Inc. · Melbourne, Victoria · NCT07905053

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Relieving a blocked pancreatic duct in chronic pancreatitis

  This pilot study tests whether clearing a blocked pancreatic duct with endoscopy can help people with chronic pancreatitis who have mild symptoms.

  Recruiting Phase 1 Mayo Clinic · Rochester, Minnesota · NCT07810309

• Understanding brain changes in chronic pancreatitis pain

  This study tests whether central nervous system changes and neuropsychological factors help explain persistent pain in adults with chronic pancreatitis.

  Recruiting Asian Institute of Gastroenterology, India · Hyderabad, Telangana · NCT07707609

• EUS-guided pancreaticobiliary procedures with the RIVOS access device

  This study tests how the RIVOS EUS access device performs during interventional procedures for pancreatic and bile duct problems in adults.

  Recruiting Orlando Health, Inc. · Orlando, Florida · NCT07696572

• Odesa Criteria 2026: tests for autoimmune pancreatitis diagnosis

  This study checks if the OC26 scoring system can accurately diagnose autoimmune pancreatitis in adults who may have AIP or related pancreatic diseases.

  Recruiting at 2 sites Military Medical Clinical Center of the Southern Region, Ukraine · Odesa and 1 other locations · NCT07536841

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.